Edgewise Therapeutics (EWTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Key Insights
Critical company metrics and information
Share Price
$30.26Market Cap
$2.87 BillionTotal Outstanding Shares
94.69 Million SharesTotal Employees
108Dividend
No dividendIPO Date
March 26, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.edgewisetx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $299.35 Million |
Net Cash Flow From Investing Activities | $-178.59 Million |
Net Cash Flow | $11.85 Million |
Net Cash Flow From Operating Activities | $-108.90 Million |
Net Cash Flow From Financing Activities, Continuing | $299.35 Million |
Net Cash Flow From Operating Activities, Continuing | $-108.90 Million |
Net Cash Flow, Continuing | $11.85 Million |
Net Cash Flow From Investing Activities, Continuing | $-178.59 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $147.15 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $-124.29 Million |
Diluted Earnings Per Share | $-1.50 |
Basic Earnings Per Share | $-1.50 |
Other Operating Expenses | $28.87 Million |
Basic Average Shares | $91.99 Million |
Diluted Average Shares | $91.99 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Revenues | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-124.29 Million |
Research and Development | $118.28 Million |
Operating Income/Loss | $-147.15 Million |
Income/Loss From Continuing Operations After Tax | $-124.29 Million |
Net Income/Loss Attributable To Parent | $-124.29 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-124.29 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Accounts Payable | $5.65 Million |
Assets | $511.28 Million |
Liabilities And Equity | $511.28 Million |
Noncurrent Liabilities | $3.45 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $488.88 Million |
Equity | $488.88 Million |
Noncurrent Assets | $11.85 Million |
Current Liabilities | $18.96 Million |
Other Current Liabilities | $7.12 Million |
Wages | $6.18 Million |
Liabilities | $22.41 Million |
Other Non-current Assets | $1.88 Million |
Fixed Assets | $9.97 Million |
Current Assets | $499.44 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.